Logo image of PRTA

PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRTA - IE00B91XRN20 - Common Stock

9.26 USD
+0.06 (+0.65%)
Last: 1/15/2026, 8:08:48 PM
9.26 USD
0 (0%)
After Hours: 1/15/2026, 8:08:48 PM
Fundamental Rating

3

PRTA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. PRTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PRTA has reported negative net income.
  • In the past year PRTA has reported a negative cash flow from operations.
  • In the past 5 years PRTA reported 4 times negative net income.
  • PRTA had negative operating cash flow in 4 of the past 5 years.
PRTA Yearly Net Income VS EBIT VS OCF VS FCFPRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

  • PRTA has a Return On Assets of -79.53%. This is in the lower half of the industry: PRTA underperforms 66.86% of its industry peers.
  • The Return On Equity of PRTA (-95.07%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.53%
ROE -95.07%
ROIC N/A
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
PRTA Yearly ROA, ROE, ROICPRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTA Yearly Profit, Operating, Gross MarginsPRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

  • PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRTA has been increased compared to 1 year ago.
  • PRTA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRTA Yearly Shares OutstandingPRTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRTA Yearly Total Debt VS Total AssetsPRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • PRTA has an Altman-Z score of -1.17. This is a bad value and indicates that PRTA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of PRTA (-1.17) is comparable to the rest of the industry.
  • PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.17
ROIC/WACCN/A
WACC7.54%
PRTA Yearly LT Debt VS Equity VS FCFPRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.61 indicates that PRTA has no problem at all paying its short term obligations.
  • PRTA has a Current ratio of 6.61. This is in the better half of the industry: PRTA outperforms 67.61% of its industry peers.
  • A Quick Ratio of 6.61 indicates that PRTA has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 6.61, PRTA is in the better half of the industry, outperforming 68.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.61
Quick Ratio 6.61
PRTA Yearly Current Assets VS Current LiabilitesPRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for PRTA have decreased strongly by -85.89% in the last year.
  • PRTA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -91.16%.
  • Measured over the past years, PRTA shows a very strong growth in Revenue. The Revenue has been growing by 178.96% on average per year.
EPS 1Y (TTM)-85.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
Revenue 1Y (TTM)-91.16%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%148.97%

3.2 Future

  • Based on estimates for the next years, PRTA will show a small growth in Earnings Per Share. The EPS will grow by 6.47% on average per year.
  • The Revenue is expected to decrease by -6.53% on average over the next years.
EPS Next Y-109.62%
EPS Next 2Y36.21%
EPS Next 3Y17.59%
EPS Next 5Y6.47%
Revenue Next Year-92.13%
Revenue Next 2Y-14.95%
Revenue Next 3Y-37.69%
Revenue Next 5Y-6.53%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PRTA Yearly Revenue VS EstimatesPRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
PRTA Yearly EPS VS EstimatesPRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • PRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTA Price Earnings VS Forward Price EarningsPRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTA Per share dataPRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PRTA's earnings are expected to grow with 17.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.21%
EPS Next 3Y17.59%

More info and screens

0

5. Dividend

5.1 Amount

  • PRTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PROTHENA CORP PLC

NASDAQ:PRTA (1/15/2026, 8:08:48 PM)

After market: 9.26 0 (0%)

9.26

+0.06 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-18
Inst Owners79.92%
Inst Owner Change-0.02%
Ins Owners19.38%
Ins Owner Change45.8%
Market Cap498.47M
Revenue(TTM)11.79M
Net Income(TTM)-280.46M
Analysts75.38
Price Target20.74 (123.97%)
Short Float %10.83%
Short Ratio7.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.94%
Min EPS beat(2)-28.86%
Max EPS beat(2)2.98%
EPS beat(4)1
Avg EPS beat(4)-10.08%
Min EPS beat(4)-28.86%
Max EPS beat(4)2.98%
EPS beat(8)3
Avg EPS beat(8)21.35%
EPS beat(12)6
Avg EPS beat(12)43.16%
EPS beat(16)6
Avg EPS beat(16)21.31%
Revenue beat(2)0
Avg Revenue beat(2)-41.76%
Min Revenue beat(2)-64.33%
Max Revenue beat(2)-19.2%
Revenue beat(4)0
Avg Revenue beat(4)-52.91%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-19.2%
Revenue beat(8)1
Avg Revenue beat(8)86.12%
Revenue beat(12)3
Avg Revenue beat(12)64.36%
Revenue beat(16)3
Avg Revenue beat(16)25.69%
PT rev (1m)0%
PT rev (3m)69.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.51%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-79.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-46.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.29
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)-4.61
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS0.22
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.53%
ROE -95.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.16%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.61
Quick Ratio 6.61
Altman-Z -1.17
F-Score3
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)132.78%
Cap/Depr(5y)92.67%
Cap/Sales(3y)1.38%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.18%
EPS Next Y-109.62%
EPS Next 2Y36.21%
EPS Next 3Y17.59%
EPS Next 5Y6.47%
Revenue 1Y (TTM)-91.16%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%148.97%
Revenue Next Year-92.13%
Revenue Next 2Y-14.95%
Revenue Next 3Y-37.69%
Revenue Next 5Y-6.53%
EBIT growth 1Y-32.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-113.92%
OCF growth 3YN/A
OCF growth 5YN/A

PROTHENA CORP PLC / PRTA FAQ

What is the ChartMill fundamental rating of PROTHENA CORP PLC (PRTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRTA.


What is the valuation status for PRTA stock?

ChartMill assigns a valuation rating of 0 / 10 to PROTHENA CORP PLC (PRTA). This can be considered as Overvalued.


What is the profitability of PRTA stock?

PROTHENA CORP PLC (PRTA) has a profitability rating of 0 / 10.